Literature DB >> 9767644

Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.

C Agouridas1, A Denis, J M Auger, Y Benedetti, A Bonnefoy, F Bretin, J F Chantot, A Dussarat, C Fromentin, S G D'Ambrières, S Lachaud, P Laurin, O Le Martret, V Loyau, N Tessot.   

Abstract

In the search for new antibiotics active against macrolide-resistant pneumococci and Haemophilus influenzae, we synthesized a new class of 3-oxo-6-O-methylerythromycin derivatives, so-called "ketolides". A keto function was introduced in position 3 after removal of L-cladinose, a sugar which has long been thought essential. Further modifications of the macrolactone backbone allowed us to obtain three different series of 9-oxime, 11,12-carbamate, and 11, 12-hydrazonocarbamate ketolides. These compounds were found to be very active against penicillin/erythromycin-resistant pneumococci and noninducers of MLSB resistance. The 11,12-substituted ketolide 61 (HMR 3004) demonstrated a potent activity against multiresistant pneumococci associated with a well-balanced activity against all bacteria involved in respiratory infections including H. influenzae, Mycoplasma catarrhalis, group A streptococci, and atypical bacteria. In addition HMR 3004 displayed high therapeutic activity in animals infected by all major strains, irrespective of their resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767644     DOI: 10.1021/jm980240d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Authors:  Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

3.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics.

Authors:  Dražen Pavlović; Stjepan Mutak; Daniele Andreotti; Stefano Biondi; Francesca Cardullo; Alfredo Paio; Elisa Piga; Daniele Donati; Sergio Lociuro
Journal:  ACS Med Chem Lett       Date:  2014-08-15       Impact factor: 4.345

5.  In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.

Authors:  Kanakeshwari Falzari; Zhaohai Zhu; Dahua Pan; Huiwen Liu; Poonpilas Hongmanee; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.

Authors:  Dražen Pavlović; Stjepan Mutak
Journal:  ACS Med Chem Lett       Date:  2011-03-15       Impact factor: 4.345

Review 7.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Authors:  Jack B Anon; Michael R Jacobs; Michael D Poole; Paul G Ambrose; Mark S Benninger; James A Hadley; William A Craig
Journal:  Otolaryngol Head Neck Surg       Date:  2004-01       Impact factor: 3.497

10.  Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives.

Authors:  Zhonghui Zheng; Deping Du; Lili Cao; Jun Liu; Xiaofang Chen
Journal:  J Antibiot (Tokyo)       Date:  2016-04-27       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.